ClinicalTrials.gg
RecruitingNCT04332822POLAR BEARUpdated Sep 19, 2024

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

A Phase 3 interventional study of R-pola-mini-CHP and R-mini-CHOP in DLBCL and Diffuse Large B Cell Lymphoma, sponsored by Nordic Lymphoma Group. Recruiting at 69 sites in 7 countries. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Nordic Lymphoma Group · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Lymphoma, Large B-Cell, Diffuse with a site in Australia — 19 open to participants now, 40 under way, 13 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Australia.

Planned enrollment
28th of 87
300 · median 151
Started
2020
with 5 others
Phase 3
28 of 89
4 open now
Primary completion
2025-12
later than 4 of 39 live
Registered
46th of 89
by date

Among the 89 studies in Lymphoma, Large B-Cell, Diffuse with a site in Australia, this one is the 28th largest by planned enrollment of the 87 interventional ones that give a count, is one of 6 that started in 2020, is one of 28 in phase 3, reaches primary completion later than 4 of the 39 other live ones, and was the 46th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

19 of the 89 studies in Lymphoma, Large B-Cell, Diffuse with a site in Australia are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Lymphoma, Large B-Cell, Diffuse with a site in Australia, or all of them as a file.
02

Study summary

This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin. The duration of the screening period is up to 4 weeks. The duration of active treatment is 18 weeks in both arms, and patients will be followed up to 36 months after end of treatment. Start of enrollment is planned in Q1 2020, and the last visit of the last patient included (end of trial) is estimated in Q1 2027.

03

Conditions studied

  • DLBCL
  • Diffuse Large B Cell Lymphoma

Keywords

  • DLBCL
  • Diffuse Large B Cell Lymphoma
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment
  • confirmed lymphoma belonging to one of the following subtypes:

    1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma
    2. follicular lymphoma grade 3B
    3. T-cell/histiocyte-rich LBCL
    4. primary cutaneous DLBCL, leg type
    5. EBV-positive DLBCL, NOS
    6. primary mediastinal LBCL
    7. high grade B-cell lymphoma with MYC/BCL2 rearrangement
  • Stage II-IV disease
  • At least 1 measurable site of disease (>1.5 cm long axis)
  • No previous treatment for lymphoma
  • 0 - 3 (Grade 3 if related to DLBCL)
  • Written

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac disease: grade 3-4
  • CNS involvement at diagnosis
  • Uncontrolled serious infection
  • Impaired liver (transaminases > 3x normal upper limit or > 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (\<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment.
  • (ANC) \<1000 cells/µL or \<100,000 cells/µL, unless due to lymphoma
  • Any other prior than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment
  • Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study
  • Known to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab
  • Peripheral neuropathy grade ≥ 2
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Arm A - R-mini-CHOP

    Cycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6

    Drug: R-mini-CHOP

  • Experimental
    Arm B - R-pola-mini-CHP

    Cycles 1-6, duration 21 days * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6 * Polatuzumab vedotin 1.8 mg/kg i.v day 1 cycles 1-6

    Drug: R-pola-mini-CHP

Interventions

  • DrugR-pola-mini-CHP

    * Rituximab 375 mg/m2 iv, day 1, cycle 1. 1400 mg s c OR 375 mg/m2 iv cycles 2-6 * Cyclophosphamide 400 mg/m2 iv, day 1, cycles 1-6 * Doxorubicin 25 mg/m2 iv , day 1, cycles 1-6 * Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6 - round up to nearest 25 mg * Polatuzumab vedotin 1.8 mg/kg iv day 1 cycles 1-6

  • DrugR-mini-CHOP

    * Rituximab 375 mg/m2 i.v., day 1, cycle 1. 1400 mg s c OR 375 mg/m2 i. v. cycles 2-6 * Cyclophosphamide 400 mg/m2 i.v., day 1, cycles 1-6 * Doxorubicin 25 mg/m2 i.v., day 1, cycles 1-6 * Vincristine 1 mg i.v. (total dose), day 1, cycles 1-6 * Prednisone, 40 mg/m2 p.o, days 1-5, , cycles 1-6

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS).

    Interval between randomization date and date of documented progression, first relapse, or death of any cause

    Time frame: 2 years.

07

Study locations

52 of 69 sites recruiting
  • Border Medical Oncology Research Unit
    Albury, Australia
    Not yet recruiting
    • Anish Puliyayil · Contact
    • Anish Puliyayil · Principal investigator
  • Royal Prince Alfred Hospital
    Camperdown, Australia
    Recruiting
    • Christina Brown · Contact
    • Christina Brown · Principal investigator
  • Coffs Harbour
    Coffs Harbour, Australia
    Not yet recruiting
    • Kyle Crassini · Contact
    • Kyle Crassini · Principal investigator
  • Concord Repatriation General Hospital
    Concord, Australia
    Recruiting
    • Emma Verner · Contact
    • Emma Verner · Principal investigator
  • Tweed Valley Hospital
    Cudgen, Australia
    Not yet recruiting
    • Alejandro Arbelaez · Contact
    • Alejandro Arbelaez · Principal investigator
  • The Canberra Hospital
    Garran, Australia
    Not yet recruiting
    • Pietro Di Ciaccio · Contact
    • Pietro Di Ciaccio · Principal investigator
  • Royal Hobart Hospital
    Hobart, Australia
    Not yet recruiting
    • Anna Johnston · Contact
    • Anna Johnston · Principal investigator
  • Liverpool
    Liverpool, Australia
    Recruiting
    • Nicholas Viiala · Contact
    • Nicholas Viiala · Principal investigator
  • Bendigo
    Melbourne, Australia
    Not yet recruiting
    • Stephen Walker · Contact
    • Stephen Walker · Principal investigator
  • Northern Health
    Melbourne, Australia
    Not yet recruiting
    • Teresa Leung · Contact
    • Teresa Leung · Principal investigator
  • St Vincent's Hospital Melbourne
    Melbourne, Australia
    Recruiting
  • Western Health
    Melbourne, Australia
    Not yet recruiting
    • Christopher Leow · Contact
    • Christopher Leow · Principal investigator
  • Fiona Stanley Hospital
    Murdoch, Australia
    Not yet recruiting
    • Allison Barraclough · Contact
    • Allison Barraclough · Principal investigator
  • Orange Health
    Orange, Australia
    Not yet recruiting
    • Charmaine Wong · Contact
    • Charmaine Wong · Principal investigator
  • Royal Perth Hospital
    Perth, Australia
    Not yet recruiting
    • Michael Francis Leahy · Contact
    • Michael Francis Leahy · Principal investigator
  • Port Macquarie
    Port Macquarie, Australia
    Not yet recruiting
    • Jock Simpson · Contact
    • Jock Simpson · Principal investigator
  • Prince of Wales Hospital
    Randwick, Australia
    Recruiting
    • Annmarie Bosco · Contact
    • Annmarie Bosco · Principal investigator
  • Royal North Shore Hospital
    St Leonards, Australia
    Not yet recruiting
    • David Kliman · Contact
    • David Kliman · Principal investigator
  • Sunshine Coast University Hospital
    Sunshine Coast, Australia
    Recruiting
    • Manjunath Narayana · Contact
    • Manjunath Narayana · Principal investigator
  • Calvary Mater Newcastle
    Waratah, Australia
    Not yet recruiting
    • Aung Thant · Contact
    • Aung Thant · Principal investigator
  • Westmead
    Westmead, Australia
    Recruiting
    • Amanda Johnston · Contact
    • Amanda Johnston · Principal investigator
  • Department og Hematology, Aalborg University Hospital
    Aalborg, Denmark
    Recruiting
    • Jakob Madsen · Contactjm@rn.dk
    • Jakob Madsen · Principal investigator
  • Department of Hematology, Aarhus University Hospital
    Aarhus, Denmark
    Recruiting
  • Clinic of Hematology L-4241, Rigshospitalet
    Copenhagen, Denmark
    Recruiting
  • Sydvestjysk Sygehus
    Esbjerg, Denmark
    Recruiting
  • Regionshospitalet Holstebro
    Holstebro, Denmark
    Recruiting
    • Troels Møller Thomsen · Contacttrotho@rm.dk
    • Troels Møller Thomsen · Principal investigator
  • Department of Hematology X, Odense University Hospital
    Odense, Denmark
    Recruiting
  • Department of Hematology, Zeeland University Hospital Roskilde
    Roskilde, Denmark
    Recruiting
  • Vejle Sygehus
    Vejle, Denmark
    Recruiting
  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
    Helsinki, Finland
    Recruiting
  • Kuopio University Hospital
    Kuopio, Finland
    Recruiting
  • Oulu University Hospital
    Oulu, Finland
    Recruiting
  • Tampere University Hospital
    Tampere, Finland
    Recruiting
  • Turku University Hospital
    Turku, Finland
    Recruiting
  • Centro di riferimento oncologico di Aviano
    Aviano, Italy
    Recruiting
    • Michele Spina · Contactmspina@cro.it
    • Michele Spina · Principal investigator
  • Istituto Tumori "Giovanni Paolo II" I.R.C.C.S Bari
    Bari, Italy
    Recruiting
  • The G.O.M. Bianchi-Melacrino-Morelli in Reggio Calabria
    Calabria, Italy
    Not yet recruiting
  • Ospedale San Gerardo di Monza
    Monza, Italy
    Recruiting
    • Silvia Anna Maria Bolis · Contacts.bolis@asst-monza.it
    • Silvia Anna Maria Bolis · Principal investigator
  • Azienda Ospedaliera Univeristaria Federico II di Napoli
    Napoli, Italy
    Recruiting
  • Istituto Nazionale Tumori "Fondazione Pascale" Napoli
    Napoli, Italy
    Recruiting
  • Azienda Ospedaliera San Camillo Forlanini di Roma
    Roma, Italy
    Recruiting
  • IRCCS San Raffaele Scientific Institute
    Segrate, Italy
    Recruiting
  • Azienda Sanitaria Universitaria Integrata di Trieste
    Trieste, Italy
    Recruiting
  • AOU San Luigi Gonzaga - Orbassano University of Turin
    Turin, Italy
    Recruiting
  • Azienda Sanitaria Universitaria Integrata di Udine
    Udine, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, Italy
    Recruiting
  • Auckland City Hospital
    Grafton, New Zealand
    Not yet recruiting
    • Henry Ngu · Contact
    • Henry Ngu · Principal investigator
  • Wellington Blood and Cancer Centre
    Wellington, New Zealand
    Not yet recruiting
    • Jina Hayden · Contact
    • Jina Hayden · Principal investigator
  • Haukeland Universitetshospital
    Bergen, Norway
    Recruiting
  • Kalnes Hospital (Østfold)
    Grålum, Norway
    Recruiting
  • Sykehuset Innlandet
    Innlandet, Norway
    Recruiting
  • Akershus University Hospital
    Oslo, Norway
    Recruiting
  • Avd. for Kreftbehandling, Oslo universitetssykehus
    Oslo, Norway
    Recruiting
    • Julian Hamfjord · ContactUXHAJU@ous-hf.no
    • Julian Hamfjord · Principal investigator
  • Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus
    Stavanger, Norway
    Recruiting
  • Kreftklinikken, St Olavs Hospital
    Trondheim, Norway
    Recruiting
  • Sykehuset i Vestfold
    Tønsberg, Norway
    Recruiting
    • Marit Rinde · ContactMRIN@siv.no
    • Marit Rinde · Principal investigator
  • Medicinkliniken, Södra Älvsborg Sjukhus
    Borås, Sweden
    Recruiting
  • Department of Hematology and Coagulation, Sahlgrenska University Hospital
    Göteborg, Sweden
    Recruiting
  • Department of Medicine, Halmstad Country Hospital
    Halmstad, Sweden
    Recruiting
  • Department of Internal Medicine, Kalmar County Hospital
    Kalmar, Sweden
    Recruiting
  • Hematologiska Kliniken, Universitetssjukhuset
    Linköping, Sweden
    Recruiting
  • Department of Oncology, Skåne University Hospital
    Lund, Sweden
    Recruiting
  • Center of Hematology, Karolinska University Hospital
    Stockholm, Sweden
    Recruiting
  • Department of Medicine, Sunderbyn Hospital
    Södra Sunderbyn, Sweden
    Recruiting
  • Uddevalla Sjukhus
    Uddevalla, Sweden
    Recruiting
  • Cancercentrum, Norrlands universitetsjukhus
    Umeå, Sweden
    Recruiting
  • Department of Oncology, Uppsala Academic Hospital
    Uppsala, Sweden
    Recruiting
  • Varberg Hospital
    Varberg, Sweden
    Recruiting
  • Department of Oncology, Örebro University Hospital
    Örebro, Sweden
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Dec 2025, 64 months after the start.

Of 73 phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 3, 2020
StartActual
Aug 19, 2020
Primary completionEst.
Dec 28, 2025
CompletionEst.
Dec 28, 2028
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04332822
Lead sponsor
Nordic Lymphoma Group
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Apr 3, 2020
Start date
Aug 19, 2020
Primary completion
Dec 28, 2025 (estimated)
Completion
Dec 28, 2028 (estimated)
Last update
Sep 19, 2024

Study contacts

Mats Jerkeman
Contact
mats.jerkeman@med.lu.se
0046704973507
Mats Jerkeman
principal investigator · Department of Oncology, Skåne University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion